Superpower peptides available for pre-order. Get first access.

Peptide science

What are the side effects of VK2735?

Nausea, vomiting, diarrhea, and constipation led VK2735 side effects in the 13-week VENTURE trial. See rates by dose, what fades, and what is unknown.

Quick answer

Nausea was the most common VK2735 side effect in the 13-week VENTURE trial, reaching 63% at 15 mg against 20% on placebo. Most drug-related effects were mild or moderate, and digestive effects eased after dose titration. Side effects led 9.1% to stop, rising from 3% at 2.5 mg to 20% at 15 mg. Peer-reviewed safety data stop at 13 weeks, and VK2735 is investigational.

Published
November 11, 2026
Last updated
November 11, 2026

What trials show about VK2735 side effects so far

The most common side effects of VK2735 in the VENTURE injection trial were nausea, vomiting, diarrhea, and constipation. Most drug-related VK2735 side effects were mild or moderate1 and clustered in the early weeks of dose increases. Peer-reviewed safety data come from one 13-week Phase 2 trial2, so VK2735's long-term safety is not yet known.

Both side effect rates and dropouts varied with the dose.

VK2735 side effects in the VENTURE injection trial

Digestive effects led the side effects of weekly VK2735 injections in VENTURE, with nausea the most common overall1. Its safety analysis covered 175 adults with obesity or overweight1. Every dose arm topped placebo on all four effects.

Adverse event (any cause)PlaceboVK2735 2.5 mgVK2735 5 mgVK2735 10 mgVK2735 15 mg
Nausea20%26%46%37%63%
Constipation11%20%29%26%29%
Diarrhea9%31%17%20%11%
Vomiting0%9%17%17%29%

No drug-related side effect was rated life-threatening1. Digestive effects came early and eased over time1 after titration, which raises the dose in steps. Nausea peaked in week one1 of the 15 mg arm, which started at a higher dose.

Side effects led 9.1% of participants (16 of 175)1 to stop treatment. Those stops rose from 3% at 2.5 mg1 to 20% at 15 mg, against 0% on placebo. In a company-reported maintenance study, digestive effects on less frequent doses were not meaningfully different from placebo3.

Digestive effects are the most common side effects of GLP-1-based drugs4. In obesity trials of tirzepatide, most digestive effects occurred during dose escalation5. In type 2 diabetes trials, longer, more gradual escalation6 was associated with more tolerance to nausea and vomiting.

The once-daily VK2735 tablet went through a separate trial.

Side effects reported with oral VK2735 tablets

Digestive effects were also common with the once-daily VK2735 tablet, and 99% were mild or moderate7. In the 13-week VENTURE-Oral trial, 20% of people on VK2735 stopped7 because of side effects, against 13% on placebo. These results are company-reported, with no peer-reviewed paper or posted registry results8 yet.

Longer tablet data will come from the Phase 3 SUNRISE program, initiated in October 20269. Its 68-week SUNRISE-1 trial10 is not yet recruiting.

What is not yet known about VK2735 safety

VK2735's long-term safety is not yet known. Peer-reviewed data stop at 13 weeks, and company-reported data reach 33 weeks3. VANQUISH-1, a 78-week trial of about 4,500 adults11, is expected to complete in 2027. Until then, open questions draw on VENTURE and on approved GLP-1 drugs.

These questions concern VK2735 tested in trials, and products sold online add risks of their own.

Risks of VK2735 products sold online

VK2735 sold online carries risks beyond its side effects, because no VK2735 product is approved. Anything sold under the name comes from outside legal peptide channels, with unverified contents, purity, and strength.

The FDA warns that GLP-1 drugs sold illegally online may contain the wrong ingredient21, the wrong amount, or none, and that versions labeled "for research purposes" are of unknown quality. Semaglutide vials bought online without a prescription held 7.7% to 14.37% pure drug22, against 99% on the label. Every vial also contained bacterial toxins.

With no approved VK2735 dose, no label exists to check a product against. Verified VK2735 safety information comes only from its clinical trials.

Where can I learn about peptides?

Superpower’s peptide library tracks investigational weight-loss compounds like VK2735 beside the GLP-1 drugs they build on. Each guide sets out what trials recorded about side effects and what remains untested.

Every guide is written and fact-checked by a team of health journalists and licensed clinicians. The science behind peptides explains how gut hormones like GLP-1 and GIP work, putting each trial result in context.

IMPORTANT SAFETY INFORMATION

VK2735 is an investigational drug in clinical development. It has not been approved by the FDA for any medical use, has no approved labeling, and is not prescribed, sold, or dispensed through Superpower. This page is provided for educational purposes only and does not constitute medical advice.

Approved GLP-1 receptor agonist labeling carries a boxed warning about thyroid C-cell tumors seen in rodent studies; whether this applies to people, or to VK2735, has not been established. Approved labels in this class also warn about acute pancreatitis, acute gallbladder disease, and acute kidney injury from fluid loss, such as from vomiting or diarrhea. These are class-level considerations, not findings established for VK2735.

Populations of theoretical concern based on class-level labeling, not VK2735-specific data, include people with a personal or family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia type 2 (MEN 2), and people who are pregnant. The VENTURE trial excluded people with diabetes or chronic pancreatitis, so its safety data do not describe those groups.

Most common side effects reported in the 13-week VENTURE Phase 2 trial: nausea, vomiting, diarrhea, and constipation. Most drug-related side effects were mild or moderate. Safety data beyond 13 weeks have not been published.

This content is provided by Superpower Health for educational and informational purposes only. Superpower Health does not prescribe, sell, or facilitate access to VK2735. VK2735 is an investigational compound that is not FDA-approved; access is limited to clinical trial enrollment. This page is not a substitute for medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider.

More peptide science